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Background: Childhood peroxisomal disorders and leukodystrophies are devastating diseases characterized by
dysfunctional lipid metabolism. Plasmalogens (ether glycerophosphoethanolamine lipids) are decreased in these
genetic disorders. The biosynthesis of plasmalogens is initiated in peroxisomes but completed in the endoplasmic
reticulum. We therefore undertook a study to evaluate the ability of a 3-substituted, 1-alkyl, 2-acyl glyceryl ether
lipid (PPI-1011) to replace plasmalogens in rhizomelic chrondrodysplasia punctata type 1 (RCDP1) and rhizomelic
chrondrodysplasia punctata type 2 (RCDP2) lymphocytes which possess peroxisomal mutations culminating in
deficient plasmalogen synthesis. We also examined plasmalogen synthesis in Pelizaeus-Merzbacher disease (PMD)
lymphocytes which possess a proteolipid protein-1 (PLP1) missense mutation that results in abnormal PLP1 folding
and it’s accumulation in the endoplasmic reticulum (ER), the cellular site of the last steps in plasmalogen synthesis.
In vivo incorporation of plasmalogen precursor into tissue plasmalogens was also evaluated in the Pex7 mouse
model of plasmalogen deficiency.
Results: In both RCDP1 and RCDP2 lymphocytes, PPI-1011 repleted the target ethanolamine plasmalogen
(PlsEtn16:0/22:6) in a concentration dependent manner. In addition, deacylation/reacylation reactions resulted in
repletion of PlsEtn 16:0/20:4 in both RCDP1 and RCDP2 lymphocytes, repletion of PlsEtn 16:0/18:1 and PlsEtn 16:0/
18:2 in RCDP2 lymphocytes, and partial repletion of PlsEtn 16:0/18:1 and PlsEtn 16:0/18:2 in RCDP1 lymphocytes. In
the Pex7 mouse, oral dosing of labeled PPI-1011 demonstrated repletion of tissue levels of the target plasmalogen
PlsEtn 16:0/22:6 with phospholipid remodeling also resulting in significant repletion of PlsEtn 16:0/20:4 and PlsEtn
16:0/18:1. Metabolic conversion of PPI-1011 to the target plasmalogen was most active in the liver.
Conclusions: Our data demonstrate that PPI-1011 is activated (removal of 3-substitution) and converted to PlsEtn
in vitro in both RCDP1 and RCDP2 lymphocytes and in vivo in the Pex7 mouse model of RCPD1 effectively
bypassing the peroxisomal dysfunction present in these disorders. While PPI-1011 was shown to replete PlsEtns
16:0/x, ether lipid precursors of PlsEtn 18:0/x and PlsEtn 18:1/x may also be needed to achieve optimal clinical
benefits of plasmalogen replacement in these complex patient populations. In contrast, only limited plasmalogen
replacement was observed in PMD lymphocytes suggesting that the effects of protein misfolding and
accumulation in the ER negatively affect processing of plasmalogen precursors in this cellular compartment.
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The peroxisome disorder, rhizomelic chrondrodysplasia
punctata (RCDP) is a devasting disease characterized by
severe growth retardation and developmental delays. Most
children do not survive beyond 10 years of age and death
is often secondary to respiratory illnesses [1]. The clinical
features of RCDP are a direct result of plasmalogen defi-
ciency. Two peroxisomal enzymes, acyl CoA:dihydroxya-
cetonephosphate acyltransferase (GNPAT; EC 2.3.1.42)
and alkyl-dihydroxyacetone phosphate synthase (AGPS;
EC 2.5.1.26), are critical for the committing steps of ether
lipid plasmalogen synthesis [2]. RCDP is a heterogeneous
autosomal recessive disorder [3-5] most commonly caused
by defects in the PEX7, the peroxisome transporter for
AGPS (RCDP1), but also by defects in the enzymes them-
selves, GNPAT, (RCDP2) or AGPS (RCDP3). After synth-
esis of alkylglycerol precursors in the peroxisome, the
synthesis of ether phospholipids are completed in the ER.
Nevertheless, the only known inherited defects in plasma-
logen synthesis are the peroxisomal defects.
Recently, we performed a lipidomics analysis [6] in
Pelizaeus-Merzbacher disease (PMD) fibroblasts and
lymphocytes [7-9], in which we demonstrated significant
reduction in plasmalogen levels. However the etiology
for this plasmalogen deficiency is unknown.
Since there are no treatments for these disorders, we
undertook an evaluation of the ability of PPI-1011, a
DHA-containing ether lipid plasmalogen precursor
which bypasses the requirement for peroxisomes, to
augment deficient cellular plasmalogens in RCDP1,
RCDP2 and PMD lymphocytes and in the murine Pex7
model of RCDP1 [10].
Materials and methods
Cell Culture
Control lymphocytes (Coriell GM13072 and GM02184);
PMD lymphocytes (Coriell GM09545; PLP1 c.767C > T
or p.P215S); RCDP1 lymphocytes (Coriell GM09291;
PEX7 c.870 871insCAA/875T > A or p.C290 E291insQ/
L292X and show a severe plasmalogen synthesis defect)
and RCDP2 lymphocytes (Coriell GM16776; homozy-
gous for GNPT c.1280-3T > G predicted to encode an
in-frame protein p.427 507 del and showing a milder
plasmalogen synthesis defect) [11] were kept as suspen-
sion cultures (25 ml flasks) in RPMI 1640 (Hyclone)
supplemented with 10% FBS and 1% antibiotic/antimy-
cotic, at 37°C in a 5% CO2 incubator [6].
Lymphocytes were harvested (1280 ×g) and washed
twice with cold phosphate buffered saline (PBS) and the
stored at -80°C for subsequent lipidomic analyses.
Plasmalogen Synthesis
To monitor plasmalogen synthesis lymphocytes were
incubated with 20 or 100 uM PPI-1011 [7,12] or PPI-
1038 for 72 hr and incorporation into cellular plasmalo-
gens measured. PPI-1038 is a stable isotopic version of
PPI-1011, an ether lipid plasmalogen precursor with a
[
13C3]glycerol backbone (G), a [
13C16]palmitic ether link-
age (P) at sn-1, a [
13C3]DHA (D) acyl linkage at sn-2,
and a lipoic acid acyl linkage at sn-3 to stabilize the pre-
cursor. Incorporation into the target plasmalogen was
monitored as [
13C22]16:0/22:6 PlsEtn (P-G-D). Lipid
remodeling, which involves deacylation at sn-2 (i.e.
removal of [
13C3]DHA) and reacylation with other fatty
acids was monitored as [
13C19]16:0/x PlsEtns (P-G).
Acylation of unlabelled plasmalogen precursors with the
released [
13C3]DHA was monitored as [
13C3]x/22:6
PlsEtns (D). The specificity of these measurements was
achieved via specific LC-MS/MS MRMs.
Pex7 Mice
Levels of plasmalogens in different tissues were measured
in Pex7 (18 to 24 g) mice [10] and both heterozygote and
wild-type controls (24-30 g). No differences in plasmalo-
gen levels were noted between wild-type and heterozy-
gote controls. In the subsequent experiment, Pex7 mice
and heterozygote controls were orally dosed by gavage
with PPI-1038 (100 mg/kg; 10 mg/ml Neobee M5; Spec-
trum Chemical Mfg.) daily for 3 days. On day 4, tissues
were harvested for plasmalogen analysis. All mice were
studied between ages 2 and 3 months. The mouse studies
were conducted under the McGill University Animal
Care Committee approved protocol 5538 entitled “Study
of PEX7 deficient mice as models for RCDP’’.
Plasmalogen Analyses
For plasmalogen analyses, cells or pulverized tissues
were sonicated in 1 mL of PBS + 0.5 mL methanol.
Next, 2 mL tert-butylmethylether were added and the
samples capped and shaken (1400 rpm) for 10 min at
room temperature. The samples were then centrifuged
for 8 min in a clinical centrifuge and 1 ml of the upper
organic layer isolated for LC-MS/MS analyses of endo-
genous and labeled ethanolamine plasmalogens as
reported previously [7,12-14].
Data Analyses
In vitro data are presented as mean ± SEM for groups of
six to eight 25 ml flasks. Since standards are not avail-
able for the lipidomic analysis of diverse plasmalogens,
these were normalized to the housekeeping metabolite
PtdEtn 16:0/18:0. Data were analyzed by 1-way
ANOVA, followed by the Tukey-Kramer test to deter-
mine differences between groups.
In vivo data are presented as mean ± SEM for groups
of 6 for plasmalogen levels and as mean ± SD for
groups of 4 mice for the precursor labeling study. HO
comparisons to HT mice were conducted with a t-test.
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Ethanolamine Plasmalogens in RCDP Lymphocytes
In RCDP1 lymphocytes, PlsEtns 16:0/x were all
decreased to approximately 25% of control (Figure 1).
The ether lipid plasmalogen precursor, PPI-1011 effec-
tively restored PlsEtn 16:0/22:6 and PlsEtn 16:0/22:4 and
partially restored PlsEtn 16:0/18:2 and PlsEtn 16:0/18:1
(Figure 1).
In RCDP2 lymphocytes PlsEtns 16:0/x were all
decreased to approximately 60% of control (Figure 1).
All plasmalogens were augmented beyond control levels
with PPI-1011 treatment (Figure 1).
In both RCDP1 and RCDP2 lymphocytes, PPI-1011
did not augment PlsEtns 18:0/x or PlsEtns 18:1/x (data
not shown).
Ethanolamine Plasmalogen Synthesis in RCDP and PMD
Lymphocytes




13C3]-DHA) and remodeled (P-G)
PPI-1038, into the target plasmalogen (PlsEtn 16:0/22:6)
was significantly increased in both RCDP1 and RCDP2
lymphocytes (Figure 2). The labeled DHA pool formed
by deacylation at sn-2 was significantly increased in
both RCDP1 and RCDP2 lymphocytes (Figure 2). How-
ever, increased utilization of this DHA pool for reacyla-
tion at sn-2 was only observed in PlsEtn 18:1/22:6
(Figure 2).
Incorporation of intact labeled (P-G-D) and remodeled
(P-G) PPI-1038, into the target plasmalogen (PlsEtn
16:0/22:6) was significantly increased in PMD lympho-
cytes (Figure 3), but much less than that observed with
RCDP lymphocytes (Figure 2).
Figure 1 Ethanolamine plasmalogen levels in RCDP1 and
RCDP2 lymphocytes with 0, 20 or 100 μM PPI-1011 for 72 hr.
N = 8. Mean ± SEM. All basal decrements and PPI-1011-dependent
increases were significantly (p < 0.01) from control lymphocytes and
from 0 μM PPI-1011, respectively. 16:0 (palmitic acid), 18:1 (oleic
acid), 18:2 (linoleic acid), 20:4 (arachidonic acid), 22:6
(docosahexaenoic acid; DHA).
Figure 2 Incorporation of PPI-1038 (100 μM; 72 hr) into the
16:0/22:6, 18:0/22:6 and 18:1/22:6 plasmalogens and DHA of
RCDP1 and RCDP2 lymphocytes. N = 6. Mean ± SEM. P =[
13C16]
palmitic acid; G =[
13C3]glycerol; D = [
13C3]DHA. *, p < 0.01 vs.
control.
Figure 3 Incorporation of PPI-1038 (100 μM; 72 hr) into the
16:0/22:6, 18:0/22:6 and 18:1/22:6 plasmalogens and DHA of
PMD lymphocytes. N = 6. Mean ± SEM. P =[
13C6]palmitic acid; G =
[
13C3]glycerol; D = [
13C3]DHA. *, p < 0.01 vs. control.
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Tissue levels of PlsEtns 16:0/x were significantly
decreased in the liver, kidneys, heart, lungs, neocortex
and eyes of Pex7 mice (Figure 4). These decreases were
approximately 50% except for PlsEtns 16:0/22:6 and
18:0/22:6 which were reduced to 15 to 30% of control in
the eye and neocortex (Figure 4).
Administration of PPI-1038, daily for 3 days, resulted
in significant labeling of the PlsEtn 16:0/22:6 pool in all
tissues. The major labeled form in the adrenal, kidney,
lung and liver was the [
13C16]palmitic acid + [
13C3]gly-
cerol labeled PlsEtn 16:0/22:6, resulting from lipid remo-
deling at sn-2. The data for the adrenal, kidney and lung
are presented in Figure 5. Much greater labeling in the
liver was observed: 24.9 ± 3.1% for heterozygote controls
and 40.3 ± 4.4% for homozygote Pex7 mice. In the case
of the brain (neocortex) and eyes, increased [
13C16]pal-
mitic acid + [
13C3]glycerol labeled PlsEtn 16:0/22:6 was
measured (Figure 6). In these tissues, the [
13C3]DHA
released by deacylation at sn-2 was incorporated into
Figure 4 Ethanolamine plasmalogen levels in Pex7 mouse tissues (liver, kidney, heart, lung, neocortex and eye).N=5P e x7 ;N=1 0
controls (2 heterozygotes + 8 wild-type). Mean ± SEM. All plasmalogen decreases were statistically significant (p < 0.05).
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(Figure 6).
Discussion
RCDP is a lethal disorder of critical peroxisomal genes
involved in ether lipid synthesis, particularly ethanola-
mine plasmalogens (PlsEtn). Strategies to replace plas-
malogens must take these deficiencies into account and
supply ether lipid precursors that are capable of bypass-
ing abnormal peroxisomal function. Our data demon-
strate that PPI-1011 can bypass the requirements for
functional peroxisomes since PPI-1011 efficiently
replaced the target PlsEtn 16:0/22:6 (Figure 7) in both
RCDP1 and RCDP2 lymphocytes. In addition, this target
plasmalogen underwent significant lipid remodeling at
sn-2 to also replenish other PlsEtns 16:0/x. No augmen-
tation of PlsEtns 18:0/x or PlsEtns 18:1/x were detected,
suggesting that a combination of 16:0, 18:0 and 18:1
ether lipid precursors may be needed to obtain the best
potential clinical outcome for plasmalogen precursors in
RCDP clinical trials.
The Pex7 hypomorphic mouse has been shown to
possess approximately 50% reductions in plasmalogens,
assayed by a procedure that does not distinguish the
multiple plasmalogen species [9]. Our LC-MS/MS ana-
lyses also demonstrated an approximate 50% decrease in
cellular pools of plasmalogens but also detected much
more dramatic decrements in DHA-containing plasma-
logens in the eye and brain. These tissues are highly
dependent upon DHA and DHA-containing plasmalo-
gens [15,16] and possess specific transport mechanisms
to import plasmalogens and plasmalogen precursors
[17,18]. Our studies with labeled PPI-1011 (PPI-1038)
demonstrated that this ether lipid precursor is orally
bioavailable and generates the target plasmalogen
(PlsEtn 16:0/22:6; Figure 6) in a number of control
mouse tissues. Our data further emphasize the impor-
tance of the liver in the synthesis of critical peroxisome-
dependent CNS plasmalogens, as previously shown for
DHA [16]. In addition this plasmalogen synthesis from
labeled PPI-1011 is augmented in Pex7 deficient mice.
The lack of lipid remodeling at sn-1 again indicates that
a cocktail of 16:0, 18:0 and 18:1 ether lipid precursors to
obtain a therapeutic effect in RCDP may be needed.
Ethanolamine plasmalogen synthesis is complicated in
that multiple cellular compartments are involved [19].
In the case of PMD, the combination of aberrant func-
tion of peroxisomes and the endoplasmic reticulum
[20,21] results in decrements in plasmalogens [7]. Our
data with PMD lymphocytes demonstrate that this com-
bination of cellular defects limits the ability of ether
Figure 5 Incorporation of [
13C16]palmitic acid and [
13C3]
glycerol from PPI-1038 (100 mg/kg/day for 3 days) into Pex7
tissue PlsEtn 16:0/22:6. N = 4. Mean ± SD. Increases in labeling in
the Pex7 mice were significant in all cases (p < 0.01). HT,
heterozygote controls; HO, homozygotes.
Figure 6 Incorporation of [
13C6]palmitic acid and [
13C3]glycerol
(*) from PPI-1038 (100 mg/kg/day for 3 days) into PlsEtn 16:0/
22:6 in the neocortex and eyes of Pex7 mice. Similarly the
incorporation of [
13C3]DHA (**) into PlsEtn 16:0/22:6, PlsEtn 18:0/22:6
and PlsEtn 18:1/22:6 is presented. N = 4. Mean ± SD. Increases in
labeling in the Pex7 mice were significant in all cases (p < 0.01). HT,
heterozygote controls; HO, homozygotes. * = [
13C16]palmitic acid +
[
13C3]glycerol labeled PlsEtn x/22:6; ** = [
13C3]DHA labeled PlsEn x/
22:6.
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is unlikely to be a fruitful therapeutic approach for
PMD.
In summary, these data demonstrate that ether lipid
precursors can bypass dysfunctional peroxisomes and
replace critical plasmalogens in RCDP lymphocytes and
in the Pex7 mouse model of RCDP1. These data also
indicate that early and sustained supply of a combina-
tion of 16:0, 18:0 and 18:1 ether lipid precursors may be
the optimal translational path for a clinical study. This
is a hypothesis that we will first validate in the Pex7
mouse. Our data also suggest that plasmalogen replace-
ment in PMD with ether lipid precursors is unlikely to
be a viable strategy.
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